6.2 Pediatric & Neonatal Pharmacotherapy

Developmental Pharmacokinetics in Pediatrics

Children are emphatically not "miniature adults." The dynamic, non-linear physiological changes that occur from the neonatal period (birth to 1 month) through infancy (1 to 12 months), childhood, and adolescence dramatically alter the absorption, distribution, metabolism, and excretion (ADME) of pharmacologic therapies.

Absorption

• Gastric pH and Secretion: At birth, gastric acid secretion is minimal, rendering the gastric pH elevated (closer to neutral > 4-5). This significantly increases the bioavailability of acid-labile drugs (e.g., penicillins, ampicillin) and severely decreases the absorption of weak organic acids (e.g., phenobarbital, phenytoin). Gastric acid production and pH do not reach mature adult levels until approximately 2 to 3 years of age.
• Gastric Emptying and Motility: Gastric emptying is highly unpredictable and prolonged in premature infants and neonates, potentially delaying the peak therapeutic effect (Cmax) of enterally administered drugs.
• Skin Permeability: The stratum corneum is exceptionally thin and highly perfused in neonates, particularly premature infants. Moreover, the ratio of total body surface area (BSA) to total body mass is significantly higher in children. This anatomical difference leads to dramatically increased systemic absorption of topical agents, putting infants at severe risk for systemic toxicity (e.g., systemic adrenal suppression from topical corticosteroids, neurotoxicity from hexachlorophene, or methemoglobinemia from topical benzocaine).

Distribution

• Total Body Water (TBW): TBW accounts for approximately 80-85% of body weight in premature neonates, 75% in full-term neonates, and gradually decreases to the adult level of 55-60% by 12 years of age.
• Hydrophilic Drugs: The expansive extracellular fluid (ECF) compartment in neonates necessitates a substantially higher weight-based dose (mg/kg) for hydrophilic drugs like aminoglycosides (gentamicin, amikacin, tobramycin) and beta-lactams to achieve target peak serum concentrations. Conversely, the lower body fat percentage in infants means highly lipophilic drugs (like diazepam) have a smaller Vd compared to adults.
• Protein Binding and Kernicterus: Neonates have inherently lower concentrations of plasma proteins (albumin and alpha-1 acid glycoprotein) and decreased binding affinity. This leads to a higher free (active) fraction of highly protein-bound drugs (e.g., phenytoin, valproic acid). Most critically, highly protein-bound drugs such as ceftriaxone and sulfonamides (e.g., sulfamethoxazole) competitively displace endogenous bilirubin from albumin. Because the neonatal blood-brain barrier is immature and porous, elevated unbound, unconjugated bilirubin readily crosses into the brain, causing a catastrophic and fatal encephalopathy known as kernicterus. Consequently, ceftriaxone is strictly contraindicated in neonates.

Metabolism

• Phase I Reactions (CYP450 system): Cytochrome P450 enzyme activity is generally low at birth but undergoes rapid, differential maturation during infancy. For instance, CYP3A4 activity surges after the first week of life, while CYP1A2 matures much later. By early childhood (toddler years), the overall metabolic rate for many CYP enzymes actually surpasses adult levels, often necessitating more frequent dosing intervals or higher weight-based doses (e.g., higher clearance of phenytoin or carbamazepine in children).
• Phase II Reactions: Glucuronidation capacity is profoundly immature at birth and takes up to 3 years to fully develop. This delayed maturation was the root cause of the infamous "Gray Baby Syndrome," a fatal cardiovascular collapse caused by chloramphenicol accumulation because neonates could not conjugate and clear the drug. Conversely, the sulfation pathway is well-developed at birth. Acetaminophen, primarily metabolized by glucuronidation in adults, is safely and primarily metabolized via sulfation in neonates.

Elimination

Glomerular filtration rate (GFR) and active tubular secretion are markedly reduced at birth, particularly in premature infants (GFR ~ 2-4 mL/min in neonates). Renal function undergoes rapid ontogeny during the first weeks of life, reaching mature adult values (when indexed to BSA) by 6 to 12 months. Medications cleared primarily by renal filtration (e.g., vancomycin, aminoglycosides, fluconazole) require extended dosing intervals (e.g., every 12, 18, or 24 hours instead of every 8 hours) in neonates to prevent toxic accumulation.

Neonatal Sepsis: Evidence-Based Management

Neonatal sepsis is a leading cause of global infant morbidity and mortality. Early-onset sepsis (EOS) presents within the first 72 hours of life and involves organisms transmitted vertically from the maternal genitourinary tract during labor.

Pathogens Driving Early-Onset Sepsis (EOS):

• Streptococcus agalactiae (Group B Streptococcus - GBS)
• Escherichia coli and other enteric Gram-negative rods
• Listeria monocytogenes

Empiric Pharmacotherapy for EOS:

• The absolute standard empiric regimen is Ampicillin plus an Aminoglycoside (typically Gentamicin). Ampicillin provides indispensable coverage against GBS, Listeria, and susceptible Enterococcus. Gentamicin yields excellent synergy for Gram-positive organisms and robust Gram-negative coverage, including E. coli.
• If meningitis is strongly suspected, Ampicillin plus Cefotaxime may be utilized, as cefotaxime exhibits superior CNS penetration compared to aminoglycosides without the biliary risks of ceftriaxone.
• Contraindication Alert: Ceftriaxone must NEVER be used in neonates due to the aforementioned risk of kernicterus. Furthermore, ceftriaxone can precipitate with calcium-containing intravenous fluids (such as parenteral nutrition), causing fatal particulate pulmonary emboli.
• If maternal history suggests active genital herpes (HSV), empiric intravenous Acyclovir must be rapidly initiated.

Late-onset sepsis (LOS) occurs after 72 hours of life and is heavily influenced by the hospital environment (NICU flora). Coverage must account for Staphylococcus aureus (including MRSA), coagulase-negative staphylococci (CONS) especially if indwelling central lines are present, and resistant Gram-negative bacilli (e.g., Pseudomonas aeruginosa, Klebsiella). Empiric therapy frequently shifts to Vancomycin plus an Aminoglycoside (or an antipseudomonal beta-lactam like Cefepime).

Excipient Toxicity and High-Alert Pediatric Medications

• Benzyl Alcohol: Used as a preservative in multi-dose vials and flush solutions. Neonates cannot metabolize benzyl alcohol, leading to accumulation of benzoic acid and fatal Gasping Syndrome (characterized by metabolic acidosis, respiratory distress, gasping respirations, and cardiovascular collapse).
• Propylene Glycol: Found in IV formulations of lorazepam, phenobarbital, and phenytoin. Accumulation in pediatrics causes hyperosmolality, lactic acidosis, and seizures.
• Codeine and Tramadol: Completely contraindicated in children <12 years, and in children <18 years following tonsillectomy or adenoidectomy. Ultra-rapid metabolizers (due to CYP2D6 genetic polymorphisms) convert massive amounts of the prodrug into active morphine or O-desmethyltramadol, resulting in profound, fatal respiratory depression.
• Promethazine: Boxed warning and contraindicated in children <2 years due to the severe risk of fatal respiratory depression.
• Valproic Acid: Carries a massively increased risk of fatal hepatotoxicity in children under 2 years of age, especially those with underlying mitochondrial disorders.
• Tetracyclines: Contraindicated in children <8 years of age due to strong binding to calcium in developing tissues, causing permanent severe tooth discoloration and enamel hypoplasia. The solitary, strict exception is the treatment of suspected Rocky Mountain Spotted Fever (RMSF), where short-course doxycycline is the definitive, life-saving drug of choice regardless of patient age.